Accession Number:

ADA383096

Title:

Efficacy of Galectin-3C in Mouse Model of Metastatic Breast Cancer

Descriptive Note:

Annual rept. 1 Jul 1998-30 Jun 1999

Corporate Author:

NORTHERN CALIFORNIA INST FOR RESEARCH AND EDUCATION SAN FRANCISCO

Personal Author(s):

Report Date:

1999-07-01

Pagination or Media Count:

13.0

Abstract:

The goal of this research is to evaluate a potential therapeutic agent for breast cancer based on the lectin galectin-3. The hypothesis to be tested is that therapy with an N-terminally truncated form of galectin-3 galectin-3C will be efficacious for inhibition of metastases. The overall purpose of the research is to determine the efficacy, safety and mechanism of action of galectin-3C in treatment of metastatic breast cancer. To this end, recombinant galectin-3 was produced from which galectin-3C was derived by collagenase enzyme digestion and affinity chromatography. For ELISA detection of injected galectin-3C in nude mice, chickens were immunized with galectin-3C but the response yielded only low affinity antibody. An alternative detection strategy was developed by metabolically labeling galectin-3 with 35 methionine prior to collagenase cleavage. The maximum tolerated dose of galectin-3C in nude mice at 5 days was determined to be a minimum of 125 mgkg without adverse effects.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE